vabicaserin

06/01/2014 - "This is the first study of efficacy, safety and tolerability of vabicaserin in adults with acute schizophrenia. "
06/01/2014 - "A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia."
04/23/2014 - "In conclusion, the updated quantitative systems pharmacology model of PANSS informed the clinical development decision of vabicaserin in schizophrenia. "
04/23/2014 - "The model predicted a concentration-dependent improvement of positive and negative syndrome scales (PANSS) in schizophrenia monotherapy with vabicaserin. "
12/01/2010 - "Vabicaserin is a potent 5-hydroxytryptamine(2C) agonist that is currently being developed for the treatment of the psychotic symptoms of schizophrenia. "

01/01/2017 - "Vabicaserin, a 5-HT2CR agonist has been in development for the treatment of schizophrenia and obesity, but was stopped. "
07/01/2013 - "Three 5-HT(2C) receptor agonists (lorcaserin, vabicaserin and YM348) that have been suggested to be useful in the treatment of several central nervous system diseases, including obesity and schizophrenia, were used. "

10/25/2021 - "The action on serotoninergic and GABAergic receptors will be considered as a new pharmacological target, with a possible efficacy of Vabicaserin on symptoms of psychosis. "

07/01/2013 - "Three 5-HT(2C) receptor agonists (lorcaserin, vabicaserin and YM348) that have been suggested to be useful in the treatment of several central nervous system diseases, including obesity and schizophrenia, were used. "

06/01/2014 - "Both vabicaserin doses were well tolerated with no significant safety signals and no weight gain. "
01/01/2012 - "Recently, the selective 5-HT(2C) agonist vabicaserin demonstrated clinical efficacy in a Phase II trial in schizophrenia patients without weight gain and with low EPS liability. "
06/01/2014 - "Olanzapine, but not vabicaserin, caused weight gain. "